摘要目的 探讨BRAFV600E基因突变与蛋白表达并存在甲状腺乳头状癌(PTC)患者中的表达及与临床病理特征的相关性.方法 收集164例PTC患者的癌组织,用荧光定量聚合酶链反应(PCR)及免疫组织化学法检测BRAFV600E表达,并结合其临床病理特点进行分析.结果 在PTC肿瘤组织中,86.6％ (142/164)存在BRAFV600E基因突变,80.5％ (132/164)存在BRAFV600E蛋白表达,90.1％ (130/143)的BRAFV600E基因突变患者中检测到BRAFV600E蛋白表达;其中,78.7％ (129/164)的患者同时检测到BRAFV600E基因突变及蛋白表达.同时存在BRAFV600E基因突变及蛋白表达的患者,具有较大的肿瘤病灶,更容易出现多病灶,更容易包膜侵犯,具有更高的淋巴结转移率及更晚的TNM分期(P =0.006、0.022).结论 PTC中BRAFV600E基因突变与蛋白表达具有较好的一致性,两者并存的患者具有更大肿瘤病灶,更易甲状腺包膜侵犯,更高颈部淋巴结转移率及更晚的TNM分期等临床病理特点.

abstractsObjective To investigate the correlation of the expression of BRAFV600E gene mutation and protein expression and clinicopathological features in patients with papillary thyroid carcinoma (PTC).Methods We collected 164 cases of PTC,the expression of BRAFV600E were detected by fluorescent quantitative PCR and immunohistochemical method,and combined with the clinicopathological features were analyzed.Results In PTC cancer tissues,86.6％ (142/164) had BRAFV600E gene mutation,80.5％ (132/164) had BRAFV600E protein expression,and 90.1％ (130/143) BRAFV600E gene mutation patients detected BRAFV600E protein expression.In 78.7％ (129/164) patients,BRAFV600E gene mutation and protein expression were detected at the same time.Patients with BRAFV600E gene mutation and protein expression together,the PTC primary tumor were larger;more likely to have multiple lesions,more likely to have capsular invasion;higher rate of lymph node metastasis;and more advanced TNM staging (P =0.006,0.022).Conclusion There is a good consistency between BRAFV600E gene mutation and protein expression in PTC.Patients with BRAFV600E gene mutation and protein expression together had some clinicopathological features,such as larger cancer lesion,more thyroid capsular invasion,higher rate of cervical lymph node metastasis,and more advanced TNM staging.